

**REMARKS**

In applicants' Amendment and Response dated December 15, 2005, applicants inadvertently omitted claims 56 and 57. This Amendment and Reply is made to place the original Amendment in compliance with the regulations.

Claims 31, 32, 55, as amended, and new claims 58-60 are pending in the application. Claims 1-30, 33-54, and 56-57, are canceled without prejudice as being drawn to non-elected subject matter. Applicants reserve the right to file divisional applications covering the non-elected material and any other material supported by the specification. Support is found in the specification for the amendments to claims 31, 32, and 55 and new claims 58-60. For example, the amendment to claim 31 adding the terminology "salts, hydrates, and enantiomers" finds support on page 31, lines 10-12 where illustrative compounds and their "pharmaceutically acceptable salts, hydrates, enantiomers, diastereomers, and geometric isomers thereof." The amendment to claim 31 is provided to make explicit what was already implicit in the claims. Therefore, no new matter is added.

Claim 33 stands rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement for use of the term "therapeutic agent." Without acquiescing to the rejection, applicants herein cancel claim 33 rendering the rejection moot.

It is respectfully submitted that the claims have been put in condition for allowance. Notification to this affect is earnestly solicited. The Examiner is encouraged to contact the Applicants' undersigned attorney to discuss this matter if any questions should arise upon further examination of the pending claims.

Respectfully submitted,

Date: 22 February 2006



William R. Boudreux  
Reg. No. 35,796  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel. (734) 622-1363  
Fax (734) 622-2928